Jonathan Rothbard

180 Life Sciences Corp. (NASDAQ: ATNF) filed a provisional patent describing the novel combination of CBD, or an analog thereof, with glucagon related peptide-1 (GLP-1) agonists to address the problem of obesity and weight management. CBD has been shown to reduce inflammation and stimulate satiety...

Two Stanford University scientists, Dr. Jonathan Rothbard and Professor Lawrence Steinman, announced this week they've joined forces to launch the medical cannabis company Katexco Pharmaceuticals. Katexco will be focused on developing a drug that exploits endocannabinoid and nicotine...